$2.23 Billion is the total value of Vivo Capital, LLC's 60 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 15.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc | $311,693,000 | +35.1% | 4,220,048 | 0.0% | 14.00% | +40.1% | |
| TIL | Instil Bio Inc | $223,201,000 | -7.5% | 12,486,787 | 0.0% | 10.02% | -4.0% | |
| HRMY | Buy | Harmony Biosciences Holdings Inc | $187,217,000 | +46.3% | 4,884,341 | +7.7% | 8.41% | +51.7% |
| NFH | New Frontier Health Corp | $160,589,000 | +0.5% | 14,300,000 | 0.0% | 7.21% | +4.3% | |
| AMRS | Buy | Amyris, Inc | $159,847,000 | -16.1% | 11,642,195 | +0.0% | 7.18% | -13.0% |
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $121,233,000 | -39.6% | 760,606 | -50.2% | 5.44% | -37.4% |
| ISEE | Iveric Bio Inc | $96,896,000 | +157.4% | 5,966,527 | 0.0% | 4.35% | +166.9% | |
| GTH | Genetron Holdings Ltdads | $87,807,000 | -31.2% | 6,339,860 | 0.0% | 3.94% | -28.7% | |
| TARS | Tarsus Pharmaceuticals Inc | $64,377,000 | -25.6% | 2,987,331 | 0.0% | 2.89% | -22.9% | |
| ALGS | Aligos Therapeutics Inc | $55,014,000 | -23.9% | 3,547,030 | 0.0% | 2.47% | -21.1% | |
| BOLT | Bolt Therapeutics Inc | $48,972,000 | -18.2% | 3,871,291 | 0.0% | 2.20% | -15.1% | |
| SRRA | Sierra Oncology, Inc | $42,022,000 | +12.6% | 1,917,074 | 0.0% | 1.89% | +16.8% | |
| New | Aadi Bioscience Inc | $41,917,000 | – | 1,427,213 | +100.0% | 1.88% | – | |
| SVA | Sinovac Biotech Ltd. | $38,173,000 | 0.0% | 5,900,000 | 0.0% | 1.71% | +3.8% | |
| KDMN | Sell | Kadmon Holdings Inc | $37,305,000 | +65.7% | 4,283,014 | -26.4% | 1.68% | +71.8% |
| IMPL | Impel NeuroPharma Inc | $35,137,000 | +37.6% | 2,884,789 | 0.0% | 1.58% | +42.8% | |
| OLMA | Olema Pharmaceuticals Inc | $34,135,000 | -1.5% | 1,238,575 | 0.0% | 1.53% | +2.2% | |
| AVDL | Avadel Pharmaceuticals PLCadr | $28,784,000 | +45.6% | 2,937,093 | 0.0% | 1.29% | +50.9% | |
| KALV | Sell | KalVista Pharmaceuticals Inc. | $28,651,000 | -35.8% | 1,641,913 | -11.9% | 1.29% | -33.5% |
| TERN | Terns Pharmaceuticals Inc | $27,875,000 | -15.0% | 2,675,133 | 0.0% | 1.25% | -11.8% | |
| CLDX | Sell | Celldex Therapeutics Inc | $26,156,000 | -19.3% | 484,453 | -50.0% | 1.17% | -16.3% |
| LEGN | Sell | Legend Biotech Corp Sponsoredsponsored ads | $24,711,000 | -37.1% | 488,751 | -48.9% | 1.11% | -34.7% |
| VRDN | New | Viridian Therapeutics Inc | $21,385,000 | – | 1,300,000 | +100.0% | 0.96% | – |
| New | Sera Prognostics Inc | $20,620,000 | – | 1,856,011 | +100.0% | 0.93% | – | |
| ZLAB | Sell | Zai Lab Ltd ADRadr | $18,443,000 | -40.5% | 174,999 | -0.0% | 0.83% | -38.3% |
| ACRS | Sell | Aclaris Therapeutics, Inc. | $16,934,000 | -29.8% | 940,754 | -31.5% | 0.76% | -27.3% |
| MREO | Buy | Mereo Biopharma Group PLCads | $16,715,000 | +24.9% | 6,907,189 | +63.6% | 0.75% | +29.7% |
| VRNA | Sell | Verona Pharma PLCads | $15,070,000 | -24.4% | 2,749,918 | -9.8% | 0.68% | -21.6% |
| NKTX | Nkarta Inc | $14,245,000 | -12.2% | 512,225 | 0.0% | 0.64% | -9.0% | |
| New | Dice Therapeutics Inc | $13,428,000 | – | 410,000 | +100.0% | 0.60% | – | |
| GRCL | Sell | Gracell Biotechnologies Incsponsored ads | $13,334,000 | -22.8% | 961,359 | -27.6% | 0.60% | -19.8% |
| CRIS | Curis Inc | $12,164,000 | -3.0% | 1,553,500 | 0.0% | 0.55% | +0.6% | |
| COGT | New | Cogent Biosciences Inc | $11,950,000 | – | 1,420,941 | +100.0% | 0.54% | – |
| KDNY | Chinook Therapeutics Inc | $11,129,000 | -9.6% | 872,151 | 0.0% | 0.50% | -6.2% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $11,081,000 | +70.8% | 500,732 | 0.0% | 0.50% | +77.2% | |
| CRNX | Sell | Crinetics Pharmaceuticals Inc | $10,889,000 | -67.0% | 517,280 | -70.5% | 0.49% | -65.8% |
| ARQT | Arcutis Biotherapeutics Inc | $10,358,000 | -12.5% | 433,585 | 0.0% | 0.46% | -9.2% | |
| KURA | Kura Oncology Inc | $9,838,000 | -10.2% | 525,262 | 0.0% | 0.44% | -6.8% | |
| MRUS | Merus NV | $9,724,000 | +4.4% | 442,000 | 0.0% | 0.44% | +8.4% | |
| DYN | Dyne Therapeutics Inc | $9,381,000 | -22.8% | 577,642 | 0.0% | 0.42% | -20.0% | |
| CDXS | Codexis, Inc | $9,028,000 | +2.6% | 388,144 | 0.0% | 0.40% | +6.3% | |
| ARWR | Arrowhead Pharmaceuticals Inc | $8,579,000 | -24.6% | 137,411 | 0.0% | 0.38% | -21.9% | |
| EPIX | Sell | Essa Pharma Inc | $8,449,000 | -80.9% | 1,056,067 | -31.9% | 0.38% | -80.3% |
| ZYME | Zymeworks Inc | $8,307,000 | -16.3% | 286,064 | 0.0% | 0.37% | -13.3% | |
| DSGN | Design Therapeutics | $7,800,000 | -26.1% | 530,991 | 0.0% | 0.35% | -23.4% | |
| FIXX | Homology Medicines, Inc. | $6,714,000 | +8.3% | 853,143 | 0.0% | 0.30% | +12.3% | |
| VALN | Sell | Valneva SEsponsored ads | $6,280,000 | -40.4% | 200,000 | -50.0% | 0.28% | -38.2% |
| SNDX | Syndax Pharmaceuticals Inc | $6,115,000 | +11.3% | 320,000 | 0.0% | 0.28% | +15.5% | |
| STSA | Satsuma Pharmaceuticals Inc | $5,743,000 | -33.9% | 1,232,394 | 0.0% | 0.26% | -31.4% | |
| PASG | Sell | Passage Bio Inc | $5,371,000 | -37.2% | 539,263 | -16.5% | 0.24% | -34.9% |
| ASLN | Aslan Pharmaceuticals Ltdads | $5,057,000 | -46.1% | 2,840,909 | 0.0% | 0.23% | -44.1% | |
| LRMR | Sell | Larimar Therapeutics Inc | $4,610,000 | -41.3% | 399,830 | -50.0% | 0.21% | -39.1% |
| ELEV | Elevation Oncology Inc | $3,870,000 | -42.6% | 496,843 | 0.0% | 0.17% | -40.4% | |
| EIGR | Sell | Eiger BioPharmaceuticals Inc | $3,137,000 | -79.4% | 469,588 | -73.8% | 0.14% | -78.7% |
| ORTX | Orchard Therapeutics plcads | $3,049,000 | -47.6% | 1,325,736 | 0.0% | 0.14% | -45.6% | |
| TXG | 10X Genomics Inc | $2,154,000 | -25.7% | 14,798 | 0.0% | 0.10% | -22.4% | |
| DTIL | Precision Biosciences Inc | $1,619,000 | -7.8% | 140,255 | 0.0% | 0.07% | -3.9% | |
| ZGNX | Zogenix Inc | $1,595,000 | -12.1% | 105,000 | 0.0% | 0.07% | -8.9% | |
| TCDA | Sell | Tricida, Inc. | $779,000 | +3.2% | 167,863 | -3.9% | 0.04% | +6.1% |
| MTCR | Metacrine Inc | $502,000 | -9.7% | 146,426 | 0.0% | 0.02% | -4.2% | |
| CALT | Exit | Calliditas Therapeutics ADRsponsored ads | $0 | – | -62,306 | -100.0% | -0.08% | – |
| IMVT | Exit | Immunovant Inc | $0 | – | -532,847 | -100.0% | -0.24% | – |
| CYTK | Exit | Cytokinetics Inc | $0 | – | -700,000 | -100.0% | -0.60% | – |
| NVAX | Exit | Novavax Inc | $0 | – | -88,046 | -100.0% | -0.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.